IRCT20200417047113N1
Recruiting
Phase 1
Evaluating the safety and efficacy of allogeneic NK cells on COVID-19 induced pneumonia, double blind, randomized clinical trial
Middle East Gene Therapy corporation0 sites70 target enrollmentTBD
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Middle East Gene Therapy corporation
- Enrollment
- 70
- Status
- Recruiting
- Last Updated
- 5 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •All COVID\-19 patients confirmed by CT scan with possitive RT\-PCR
Exclusion Criteria
- •Pregnancy or breastfeeding
- •Known HIV, HBV or HCV infection
- •Patients with malignant tumor, other serious systemic diseases and psychosis
- •Diabetic patients
- •Patients who are participating in other clinical trials
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 1
Application of Cord Blood Platelet Gel (CBPG) for the treatment of non-healing skin ulcers due to the cutaneous chronic GVHDIRCT20190101042197N1Royan Stem cell Technology Co.15
Recruiting
Not Applicable
Safety and efficacy of Mesenchymal Stem Cell administration in Bronchiolitis Obliterans Syndrome.IRCT20201202049568N2Tehran University of Medical Sciences10
Completed
Phase 1
Evaluation of the safety and efficacy of allogenic hematopoietic stem cell transplantation (HSCT) from HLA-mismatched related donors using alemtuzumab in patients with hematological malignancies.Hematological malignanciesJPRN-C000000357GCP-ISS HE0402 group48
Not yet recruiting
Phase 1
Assessment of the effect of allogeneic adipose derived mesenchymal stem cells along with platelet rich fibrin for perianal fistulas in treatment of perianal fistulasperianal fistula.Fistula, other specified siteM25.18IRCT20210830052332N1Iranian academic center for education culture and research24
Recruiting
Phase 2
Effect of treatmen with natural killer cells in acute myeloid leukemiaAcute Myeloid leukemia.Acute myeloblastic leukemiaC92.0IRCT20200417047113N2Middle East Gene Therapy corporation5